Nicholas S Riano1, Hannah M Borowsky1, Emily A Arnold1, Mark Olfson1, James T Walkup1, Eric Vittinghoff1, Francine Cournos1, Lindsey Dawson1, Alexander R Bazazi1, Stephen Crystal1, Christina Mangurian1. 1. Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences (Riano, Bazazi, Mangurian), School of Medicine (Borowsky, Arnold), Center for AIDS Prevention Studies (Arnold), and Department of Epidemiology and Biostatistics (Vittinghoff, Mangurian), University of California, San Francisco, San Francisco; New York State Psychiatric Institute, New York City (Olfson, Cournos); Department of Psychiatry, Vagelos College of Physicians and Surgeons (Olfson), and Mailman School of Public Health (Cournos), Columbia University, New York City; Institute for Health, Health Care Policy and Aging Research (Walkup) and Center for Health Services Research (Crystal), Rutgers University, New Brunswick, New Jersey; Kaiser Family Foundation, HIV Policy, Washington, D.C. (Dawson).
Abstract
OBJECTIVE: The objective of this study was to determine the availability and national distribution of HIV testing and counseling at substance use treatment facilities in the United States. METHODS: Analyses of data from the 2018 National Survey of Substance Abuse Treatment Services assessed HIV testing and counseling availability in U.S. substance use treatment facilities (excluding those in U.S. territories). Facilities were subcategorized by availability of mental health services and medication for opioid use disorders and compared by using logistic models. Descriptive statistics were calculated to characterize the availability of HIV testing and counseling by state, state HIV incidence, and facility characteristics. RESULTS: Among U.S. substance use treatment facilities (N=14,691), 29% offered HIV testing, 53% offered HIV counseling, 23% offered both, and 41% offered neither. Across states, the proportions of facilities offering HIV testing ranged from 9.0% to 62.8%, and the proportion offering counseling ranged from 19.2% to 83.3%. In only three states was HIV testing offered by at least 50% of facilities. HIV testing was significantly more likely to be offered in facilities that offered medication for opioid use disorder (48.0% versus 16.0% in those not offering such medication) or mental health services (31.2% versus 24.1% in those not offering such services). Higher state-level HIV incidence was related to an increased proportion of facilities offering HIV testing. CONCLUSIONS: Only three in 10 substance use treatment facilities offered HIV testing in 2018. This finding represents a missed opportunity for early identification of HIV among people receiving treatment for substance use disorders.
OBJECTIVE: The objective of this study was to determine the availability and national distribution of HIV testing and counseling at substance use treatment facilities in the United States. METHODS: Analyses of data from the 2018 National Survey of Substance Abuse Treatment Services assessed HIV testing and counseling availability in U.S. substance use treatment facilities (excluding those in U.S. territories). Facilities were subcategorized by availability of mental health services and medication for opioid use disorders and compared by using logistic models. Descriptive statistics were calculated to characterize the availability of HIV testing and counseling by state, state HIV incidence, and facility characteristics. RESULTS: Among U.S. substance use treatment facilities (N=14,691), 29% offered HIV testing, 53% offered HIV counseling, 23% offered both, and 41% offered neither. Across states, the proportions of facilities offering HIV testing ranged from 9.0% to 62.8%, and the proportion offering counseling ranged from 19.2% to 83.3%. In only three states was HIV testing offered by at least 50% of facilities. HIV testing was significantly more likely to be offered in facilities that offered medication for opioid use disorder (48.0% versus 16.0% in those not offering such medication) or mental health services (31.2% versus 24.1% in those not offering such services). Higher state-level HIV incidence was related to an increased proportion of facilities offering HIV testing. CONCLUSIONS: Only three in 10 substance use treatment facilities offered HIV testing in 2018. This finding represents a missed opportunity for early identification of HIV among people receiving treatment for substance use disorders.
Authors: Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson Journal: Am J Drug Alcohol Abuse Date: 2019-01-24 Impact factor: 3.829
Authors: Christina Mangurian; Francine Cournos; Dean Schillinger; Eric Vittinghoff; Jennifer M Creasman; Bernard Lee; Penelope Knapp; Elena Fuentes-Afflick; James W Dilley Journal: Psychiatr Serv Date: 2017-01-17 Impact factor: 3.084
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Raul N Mandler; Louise Haynes; Susan Tross; Tiffany Kyle; Dianne Gallup; Andrzej S Kosinski; Antoine Douaihy; Bruce R Schackman; Moupali Das; Robert Lindblad; Sarah Erickson; P Todd Korthuis; Steve Martino; James L Sorensen; José Szapocznik; Rochelle Walensky; Bernard Branson; Grant N Colfax Journal: Am J Public Health Date: 2012-04-19 Impact factor: 9.308
Authors: Adam W Carrico; David R Bangsberg; Sheri D Weiser; Maggie Chartier; Samantha E Dilworth; Elise D Riley Journal: AIDS Date: 2011-05-15 Impact factor: 4.177